Author:
Cao Xia,Maruyama Junki,Zhou Heyue,Fu Yanwen,Kerwin Lisa,Powers Colin,Sattler Rachel A.,Manning John T.,Singh Alok,Lim Reyna,Healy Laura D.,Johnson Sachi,Paz Cabral Elizabeth,Li Donghui,Lu Lucy,Ledesma Arthur,Lee Daniel,Richards Susan,Rivero-Nava Laura,Li Yan,Shen Weiqun,Stegman Karen,Blair Benjamin,Urata Shinji,Kishimoto-Urata Magumi,Ko Jamie,Du Na,Morais Kyndal,Lawrence Kate,Rivera Ianne,Pai Chin-I.,Bresson Damien,Brunswick Mark,Zhang Yanliang,Ji Henry,Paessler Slobodan,Allen Robert D.
Abstract
AbstractCoronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify neutralizing antibodies (nAbs) against SARS-CoV-2. We demonstrate the binding and neutralization capability of two nAbs, STI-2020 and STI-5041, against the SARS-CoV-2 WA-1 strain as well as the Alpha and Beta variants. STI-2020 and STI-5041 were protective when administered intravenously or intranasally in the golden (Syrian) hamster model of COVID-19 challenged with the WA-1 strain or Beta variant. The ability to administer nAbs intravenously and intranasally may have important therapeutic implications and Phase 1 healthy subjects clinical trials are ongoing.
Publisher
Springer Science and Business Media LLC
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献